US45257U1088 - Common Stock
IMMUNOME INC
NASDAQ:IMNM (4/18/2024, 7:01:00 PM)
After market: 17.18 0 (0%)17.18
-0.2 (-1.15%)
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 37 full-time employees. The company went IPO on 2020-10-02. The Company’s portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. Its proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of antibodies and targets. Its lead discovery programs include Oncology (IMM-ONC-01) and SARS-CoV-2 (IMM-BCP-01). Its IMM-ONC-01 is its lead oncology program targets interleukin 38 (IL-38), which is a negative regulator of inflammation capable of promoting tumor evasion of the immune system. The firm is developing an antibody cocktail derived from the B cells of COVID-19 patients who exhibited high neutralizing titers. IMM-BCP-01 targets non-overlapping regions of the Spike protein of SARS-CoV-2, which include highly conserved, subdominant epitopes. The IMM-BCP-01 program is focused on the variants of SARS-CoV-2.
IMMUNOME INC
665 Stockton Drive, Suite 300
Exton PENNSYLVANIA 19341
P: 16103213700
CEO: Purnanand D. Sarma
Employees: 37
Website: https://immunome.com/
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunome (NASDAQ:IMNM) just reported results for the fourth quarter of 2023.Imm...
Here you can normally see the latest stock twits on IMNM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: